Glucagon-like peptide-1 receptor agonist therapy is associated with improved outcomes of arteriovenous fistulae.
Journal of vascular surgeryFeb 2026
GLP-1 Research Tracker
Every clinical trial and published study on semaglutide, tirzepatide, and next-generation GLP-1 medications — curated with plain-language summaries.
234 studies tracked·6 compounds covered·Updated Jul 2026
Bridging Innovation and Practice in Type 2 Diabetes Mellitus: Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists.
Pharmaceuticals (Basel, Switzerland)Feb 2026
Comparing Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Metabolic Bariatric Surgery: A Systematic Review and Meta-Analysis.
Obesity surgeryFeb 2026
MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management-A Narrative Review.
Medicina (Kaunas, Lithuania)Feb 2026
Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRA.
Current cardiology reportsFeb 2026
Lean Mass Loss in Glucagon-Like Peptide-1/GIP Therapy: Clinical Implications for Obesity and Cardiovascular Care.
Cardiology in reviewFeb 2026
Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.
semaglutidetirzepatide
ESC heart failureFeb 2026
Lower Extremity Complications in Adults With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas: An Emulated Target Trial.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsFeb 2026
Diabetic Ketoacidosis Risk in Sodium-Glucose Cotransporter-2 Inhibitors vs Glucagon-Like Peptide-1 Receptor Agonists Initiators with CKD Stages 3-4 and Type 2 Diabetes.
Kidney360Feb 2026
Bariatric Surgery in the Era of GLP1RA: A Narrative Review.
Advances in therapyFeb 2026
Obesity-Driven Hypertension: Exploring the Mechanisms and Modern Treatment Strategies.
semaglutide
Cardiology in reviewFeb 2026
Tirzepatide ameliorates type 2 diabetes-associated male reproductive dysfunction via modulation of the Nrf2/Keap1 pathway.
tirzepatide
Toxicology researchFeb 2026
Phase 1
A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes.
orforglipron
Journal of diabetes investigationFeb 2026
Phase 3
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
survodutide
Diabetes, obesity & metabolismFeb 2026
Beyond Weight Loss: Holistic Impacts of a Digital Weight Management Programme Integrating Tirzepatide.
tirzepatide
CureusFeb 2026
Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.
survodutide
Contemporary clinical trials communicationsFeb 2026
Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity.
European journal of clinical investigationFeb 2026
Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes: Significant Early Glycemic and Cardiometabolic Benefits.
tirzepatide
CureusFeb 2026
Use of semaglutide after acute coronary syndrome: an exploratory retrospective study.
semaglutide
Journal of cardiovascular medicine (Hagerstown, Md.)Feb 2026
Incretin Mimetics in Cancer and Cardiovascular Disease: JACC: CardioOncology State-of-the-Art Review.
JACC. CardioOncologyFeb 2026
Get Weekly Research Updates
New clinical trials, study results, and plain-language summaries delivered to your inbox.
Free weekly newsletter · No spam, unsubscribe anytime